Evercore ISI raises Amazon stock price target on AI revenue growth

AWS AI revenue run rate exceeded $15B (≈10% of AWS revenue) and AWS’s chip business surpassed a $20B run rate with triple-digit YoY growth; Trainium is cited as delivering several hundred basis points of operating margin leverage over time. Evercore reiterated an Outperform with a $285 price target (Amazon market cap ~$2.48T, P/E 32.45), while Truist reiterated a Buy citing AI investments. Amazon Pharmacy added Eli Lilly’s GLP-1 Foundayo with same-day delivery and insured patients as low as $1/day, increasing competitive pressure in weight-management drugs. Bank of America notes online spending +12% YoY in March and +11% in Q1, supporting e-commerce momentum and same-day/perishables expansion.

Analysis

A large, vertically integrated platform stepping harder into adjacent businesses (cloud, logistics, retail pharmacy) creates asymmetric pressure: incumbents that sell purely into the cloud or into last‑mile/healthcare channels will see demand bifurcate into high‑volume, low‑margin commodity flows versus premium enterprise use cases. That bifurcation favors scale players with the balance sheet to absorb upfront logistics and regulatory costs but shrinks the addressable margin pool for niche specialists over 12–36 months.

If this platform pursues proprietary silicon and edge connectivity at scale, expect two measurable supply‑chain effects: (1) foundry and packaging demand reallocation toward hyperscaler specifications, tightening capacity for GPU-centric vendors over several quarters; (2) accelerating CAPEX cadence that increases fixed costs before material margin payback, meaning operating leverage will be back‑loaded and sensitive to adoption curves.

Retail expansion into prescription and same‑day categories compresses incumbents’ pricing power but also raises regulatory and compliance friction — pharmacy margins are sticky around reimbursement and insurer behavior, so any material share shift will play out more by distribution convenience and co‑payments than by instant price deflation. The short run (0–6 months) is likely dominated by execution cadence and marketing spend; the medium term (6–24 months) will reveal whether scale translates into sustainable margin expansion or just volume with higher capital intensity.

Key Decisions for Investors

• Long AMZN (core equity position, 2–4% NAV) with a 12–18 month horizon. Scale in on pullbacks of ~10–15% and hedge with 6–9 month 10% OTM puts sized at 25% of the equity position; target 30–50% upside if AI/cloud adoption and retail initiatives sustain, max pain = full equity drawdown minus put hedge.
• Pair trade: Long AMZN / Short HIMS (1:1 notional) for 6–12 months to play distribution vs. consumer telehealth pricing pressure. Size 1–2% NAV per leg; take profits on the pair if spread widens >25% in favor of AMZN or cut if both move >15% against the position — risk is HIMS clinical/regulatory wins or a broad retail selloff.
• Options play on bank exposure to e‑commerce: Buy a 3–6 month BAC call spread (near‑ATM to modestly OTM) to capture incremental payments/credit flow upside. Cost is limited premium; target 12–20% return if consumer online spend remains robust; close if macro retail indicators roll negative over a 4–6 week window.
• Idiosyncratic hedge: Buy a 9–12 month NVO put spread (moderately OTM) as insurance against faster‑than‑expected price compression in GLP‑1 markets or regulatory headwinds. Keep premium <1.5% NAV; payoff asymmetric if pharma pricing decelerates or policy risk materializes within the year.